# moderate-to-severe plaque psoriasis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis

> 1 upcoming FDA catalyst in moderate-to-severe plaque psoriasis: Can-Fite BioPharma Ltd. (CANF) on Q1 2027 (interim data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for moderate-to-severe plaque psoriasis?

1 upcoming FDA catalyst in moderate-to-severe plaque psoriasis: Can-Fite BioPharma Ltd. (CANF) on Q1 2027 (interim data readout). Press release filed with the SEC (EX-99): "The Company's lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-118358, https://www.sec.gov/Archives/edgar/data/1536196/000121390026118358/ea031201001ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2025 | [VYN202 trial start](https://sec-api.dev/pdufa/vyn202) | YARW | moderate-to-severe plaque psoriasis | completed | "In February 2025, we initiated a Phase 1b trial of VYN202 in adult subjects with moderate-to-severe plaque psoriasis." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm)) |
| late 2025 | [VYN202 topline data readout](https://sec-api.dev/pdufa/vyn202) | YARW | moderate-to-severe plaque psoriasis | scheduled | "We expect to enroll approximately 80 subjects with moderate-to-severe plaque psoriasis and to report top-line results from the placebo-controlled trial by the end of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1566044/000162828025010908/vyne-20241231.htm)) |
| December 18, 2025 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | moderate-to-severe plaque psoriasis | completed, positive | "OSAKA Japan AND CAMBRIDGE, Massachusetts, December 18, 2025 - Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000174/form6k_121825.htm)) |
| January 6, 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS | moderate-to-severe plaque psoriasis | completed, positive | "On January 6, 2026 we announced positive topline results from our Phase 3 ONWARD1 and ONWARD2 global Phase 3, multi-center, randomized, double-blind placebo-controlled clinical trials, evaluating envu in patients with PsO." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)) |
| Q3 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS | moderate-to-severe plaque psoriasis | scheduled | "In addition, envu is currently being evaluated in a Phase 2 clinical trial in patients with systemic lupus erythematosus ("SLE"), for which we expect to report topline results in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm)) |
| Q1 2027 | [Can-Fite BioPharma Ltd. interim data readout](https://sec-api.dev/companies/canf/catalysts) | CANF | moderate-to-severe plaque psoriasis | scheduled | "The Company's lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000121390026118358/ea031201001ex99-1.htm)) |

## Drugs

- [VYN202](https://sec-api.dev/pdufa/vyn202) (YARW)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate-to-severe plaque psoriasis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis

```bibtex
@misc{secapidev_indications_moderate_to_severe_plaque_psoriasis_20261116,
  title        = {moderate-to-severe plaque psoriasis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_plaque_psoriasis_20261116","title":"moderate-to-severe plaque psoriasis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
